Grail, a healthcare company specializing in multi-cancer early detection, is sued in a class action for allegedly misleading investors about the success of its NHS-Galleri trial. The trial aimed to show a reduction in late-stage cancers but failed to meet its primary endpoint, leading to a stock price drop of over 50%. The lawsuit claims Grail and executives provided overly optimistic statements and concealed negative data. Investors who bought Grail stock between May 2025 and February 2026 can seek to lead the lawsuit, which is ongoing.
Bluejay Diagnostics completed a private placement raising $8.5 million upfront, with potential additional proceeds of $15.2 million if warrants are fully exercised. The funds will support FDA approval processes, including clinical studies, and genera...
Bitcoin has fallen 50% from its all-time high, erasing about $988 billion in market value due to a mix of market-specific and macroeconomic pressures. Significant ETF outflows in the U.S. signal growing investor caution, while ongoing geopolitical te...
After AI revealed a critical flaw in Zcash's cryptographic system causing a 46% price crash, concerns arose about XRP facing a similar fate. However, RippleX developer J. Ayo Akinyele explained that XRP Ledger's upcoming privacy upgrade, Confidential...
Bitcoin treasury companies have seen a combined market value drop of $62 billion, falling from $134 billion to $72 billion, as Bitcoin trades between $60,000 and $63,000, well below previous highs. Strategy Inc. (formerly MicroStrategy) suffered the ...
Argentina's investigation into $4.78 million in Libra token transactions has been halted because the Specialized Cybercrime Prosecutor’s Office (UFECI) lacks the necessary software to conduct a detailed forensic analysis of the wallets involved. Pros...
